Chimerix, Inc. (NASDAQ:CMRX) Expected to Post Q2 2024 Earnings of ($0.23) Per Share

Chimerix, Inc. (NASDAQ:CMRX) – HC Wainwright lowered their Q2 2024 earnings per share estimates for Chimerix in a research report issued on Thursday, May 2nd. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter, down from their previous estimate of ($0.22). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Chimerix’s Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at ($1.07) EPS and FY2026 earnings at ($1.01) EPS.

Chimerix (NASDAQ:CMRX) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same quarter in the previous year, the business earned ($0.24) earnings per share.

A number of other equities research analysts have also issued reports on CMRX. StockNews.com lowered Chimerix from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Monday, February 12th.

Chimerix Price Performance

Shares of NASDAQ CMRX opened at $0.99 on Monday. The stock has a market cap of $88.73 million, a PE ratio of -1.06 and a beta of 1.13. Chimerix has a 1 year low of $0.88 and a 1 year high of $1.57. The firm has a fifty day moving average price of $1.03 and a 200-day moving average price of $1.00.

Hedge Funds Weigh In On Chimerix

A number of hedge funds and other institutional investors have recently modified their holdings of CMRX. Marquette Asset Management LLC increased its holdings in Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 22,709 shares during the last quarter. Pale Fire Capital SE grew its position in shares of Chimerix by 113.6% during the fourth quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 112,318 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Chimerix during the fourth quarter valued at about $1,348,000. Vance Wealth Inc. bought a new stake in shares of Chimerix in the fourth quarter worth about $46,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of Chimerix by 17.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after buying an additional 72,719 shares in the last quarter. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.